Amyris brought its farnesene production platform to scale, but returned to low-volume applications following financial trouble

May 24, 2018 | Case Study

Amyris is a synthetic biology company that utilizes high-throughput screening to evaluate genetically engineered strains of yeast that produce isoprenoid compounds. The company has developed software and hardware platforms that allow its scientists to design and build over 1,000 molecules per month. Over the past few years, the majority of Amyris' resources were diverted from developing new pathways and instead dedicated toward ramping up and optimizing the production of farnesene (C15H24), a platform molecule with a variety of derivatives and with both high- and low-volume applications. Amyris prioritized the high-volume derivatives in 2011 and began the construction of a 40,000 tpa capacity commercial facility named Brotas 1.

Login to View This Research

Already a Lux Client?

Sign In

Not a Lux Client?

Talk to Lux Research now and learn the benefits of becoming a member.

Lux Research

  • Helps clients find new business opportunities from emerging technologies in the physical and life sciences
  • Offers ongoing technology and market intelligence, as well as market data and consulting services
  • Now serves over 250 clients on six continents – multinational corporations, investors, governments, and SMEs
  • Has a Global reach, with offices in Boston, New York, Amsterdam, Singapore, and Tokyo
  • Combines deep technical expertise with business analysis to support strategic decisions

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 (0) 20-3460840

For APAC (Singapore)
+65 6592-6978